Hims & Hers Health, Inc. (HIMS)
Mexican Exchange · Mexico · prices in MXN · close of 23 Oct 2026
Key indicators
| Last close | MXN 516.59 |
|---|---|
| 52-week range | 240.00 – 932.00 |
| Return, 1 month / 3 months | +3.3% / −10.2% |
| Return, 1 year / 3 years | −41.6% / – |
| Trend | Uptrend |
| RSI (14) | 48 |
| Volatility (1 year) | 85.5% |
| Worst drawdown (1 year) | -72.1% |
| Average daily value traded | 1.08M MXN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hims & Hers Health is a telehealth company based in San Francisco that sells prescription treatments and personal care products directly to consumers through its websites and mobile apps. Customers consult licensed providers online and receive medications and wellness products for categories such as hair loss, sexual health, skin care, mental health and women's health. The company serves individuals seeking convenient, private access to care and recurring treatment subscriptions, and it also offers some products through retail partners.
On this site Hims & Hers Health, Inc. appears as a stock on the Mexican Exchange (Mexico), code HIMS, with prices in Mexican pesos (MXN). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hims & Hers Health, Inc. (HIMS) trades on the Mexican Exchange in Mexico. It last closed at MXN 516.59 on 23 October 2026.
Its price-based Market X-Ray is 30 out of 100 (a weak price profile), ranking 311 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 41.6% and over the last three months it fell 10.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Mexican Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 8.9% | ||
| From 52-week high | -42.7% | ||
| Momentum | 23 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.2% | ||
| 6-month return | 5.5% | ||
| 12-month return, skipping the last month | -43.5% | ||
| Stability (higher is calmer) | 2 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 85.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -72.1% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.08M MXN | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.1% |
|---|---|
| 1 month | +3.3% |
| 3 months | −10.2% |
| 6 months | +5.5% |
| 1 year | −41.6% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 512.17 / 474.51 |
|---|---|
| Golden / death cross (60 days) | Golden, 59 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 26.11 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Mexican Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.